KRW 20500.0
(2.5%)
Year | Long Term Debt | Long Term Debt Growth |
---|---|---|
2023 | 988.75 Million KRW | -40.29% |
2022 | 1.65 Billion KRW | -22.59% |
2021 | 2.13 Billion KRW | 52.79% |
2020 | 1.4 Billion KRW | -11.39% |
2019 | 1.58 Billion KRW | 25.4% |
2018 | 1.26 Billion KRW | -55.63% |
2017 | 2.84 Billion KRW | -78.43% |
2016 | 13.16 Billion KRW | 0.0% |
Year | Long Term Debt | Long Term Debt Growth |
---|---|---|
2024 Q2 | 532.76 Million KRW | 100.0% |
2024 Q1 | 774.71 Million KRW | 0.0% |
2023 Q2 | 1.47 Billion KRW | -42.86% |
2023 Q4 | 988.75 Million KRW | -20.29% |
2023 Q3 | 1.24 Billion KRW | -15.95% |
2023 FY | 988.75 Million KRW | -40.29% |
2023 Q1 | 2.58 Billion KRW | 0.0% |
2022 Q2 | - KRW | 0.0% |
2022 Q4 | - KRW | 0.0% |
2022 Q1 | - KRW | 0.0% |
2022 Q3 | - KRW | 0.0% |
2021 Q4 | - KRW | 0.0% |
2021 Q3 | - KRW | 0.0% |
Name | Long Term Debt | Long Term Debt Difference |
---|---|---|
CMG Pharmaceutical Co., Ltd. | 19.06 Billion KRW | 94.813% |
Celltrion Pharm, Inc. | 4.33 Billion KRW | 77.182% |
Huons Global Co., Ltd. | 66.94 Billion KRW | 98.523% |
DongKook Pharmaceutical Co., Ltd. | 18.74 Billion KRW | 94.727% |
Enzychem Lifesciences Corporation | 1.02 Billion KRW | 3.536% |
Humedix Co., Ltd. | 1.75 Billion KRW | 43.671% |
Boditech Med Inc. | 2.09 Billion KRW | 52.915% |
EuBiologics Co., Ltd. | 2.8 Billion KRW | 64.687% |
FutureChem Co.,Ltd | 2.61 Billion KRW | 62.258% |
Huons Co., Ltd. | 58.35 Billion KRW | 98.305% |
BNC Korea Co., Ltd. | 301.69 Million KRW | -227.739% |
AptaBio Therapeutics Inc. | 13.56 Billion KRW | 92.713% |